Table 3.

Incremental cost-effectiveness ratio and differences in quality-adjusted life years and costs

Treatment setting	Δ of costs (in USD)	Δ of QALYs	ICER
Low-dose crizanlizumab vs. placebo	6,736	-0.00046	-
Low-dose crizanlizumab+hydroxyurea vs. hydroxyurea	6,733	0.0169	398,881
High-dose crizanlizumab vs. placebo	13,476	0.0124	1,088,612
High-dose crizanlizumab+Hydroxyurea vs. hydroxyurea	13,430	0.0112	1,194,054

USD: United States Dollar; QALY: Quality adjusted life years; ICER: Incremental cost-effectiveness ratio